Chunghwa Chemical Synthesis & Biotech Co (TPE:1762) ROIC %: -16.11% (As of Dec. 2025)


TPE:1762 Chunghwa Chemical Synthesis & Biotech Co Ltd TPE:1762
58 GF Score
Price NT$38.15
GF Value NT$37.92
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Chunghwa Chemical Synthesis & Biotech Co ROIC %?

Chunghwa Chemical Synthesis & Biotech Co TPE:1762 58 ROIC % is -16.11% as of Dec. 2025. GuruFocus rates TPE:1762 with a GF Score™ of 58/100 and a GF Value™ of NT$37.92 (Fairly Valued). The stock has 8 warning signs investors should review.

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Chunghwa Chemical Synthesis & Biotech Co's annualized return on invested capital (ROIC %) for the quarter that ended in Dec. 2025 was -16.11%.

As of today (2026-07-12), Chunghwa Chemical Synthesis & Biotech Co's WACC % is 4.14%. Chunghwa Chemical Synthesis & Biotech Co's ROIC % is -7.22% (calculated using TTM income statement data). Chunghwa Chemical Synthesis & Biotech Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Chunghwa Chemical Synthesis & Biotech Co  (TPE:1762) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Chunghwa Chemical Synthesis & Biotech Co's WACC % is 4.14%. Chunghwa Chemical Synthesis & Biotech Co's ROIC % is -7.22% (calculated using TTM income statement data). Chunghwa Chemical Synthesis & Biotech Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Chunghwa Chemical Synthesis & Biotech Co ROIC % Related Terms


Chunghwa Chemical Synthesis & Biotech Co ROIC % Historical Data

* Premium members only.

The historical data trend for Chunghwa Chemical Synthesis & Biotech Co's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chunghwa Chemical Synthesis & Biotech Co ROIC % Chart

Chunghwa Chemical Synthesis & Biotech Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.53 9.37 5.31 0.13 -7.26

Chunghwa Chemical Synthesis & Biotech Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.12 -1.33 -4.39 -7.16 -16.11

TPE:1762 vs VRTX, REGN, ALNY: ROIC % Comparison

For the Biotechnology subindustry, Chunghwa Chemical Synthesis & Biotech Co's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chunghwa Chemical Synthesis & Biotech Co ROIC % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chunghwa Chemical Synthesis & Biotech Co's ROIC % distribution charts can be found below:

* The bar in red indicates where Chunghwa Chemical Synthesis & Biotech Co's ROIC % falls into.


TPE:1762
58GF Score
Chunghwa Chemical Synthesis & Biotech Co Ltd TPE:1762
ROIC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chunghwa Chemical Synthesis & Biotech Co ROIC % Calculation

Chunghwa Chemical Synthesis & Biotech Co's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2025 is calculated as:

ROIC % (A: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2024 ) + Invested Capital (A: Dec. 2025 ))/ count )
=-319.538 * ( 1 - 4.63% )/( (4395.862 + 4002.327)/ 2 )
=-304.7433906/4199.0945
=-7.26 %

where

Invested Capital(A: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4762.738 - 144.601 - ( 222.275 - max(0, 425.288 - 1441.225+222.275))
=4395.862

Invested Capital(A: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4317.353 - 98.589 - ( 216.437 - max(0, 356.706 - 1058.883+216.437))
=4002.327

Chunghwa Chemical Synthesis & Biotech Co's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Dec. 2025 is calculated as:

ROIC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-651.868 * ( 1 - 0% )/( (4088.026 + 4002.327)/ 2 )
=-651.868/4045.1765
=-16.11 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4438.664 - 97.45 - ( 253.188 - max(0, 350.635 - 1171.092+253.188))
=4088.026

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4317.353 - 98.589 - ( 216.437 - max(0, 356.706 - 1058.883+216.437))
=4002.327

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROIC % →
What does a ROIC % of -16.11% mean?
Chunghwa Chemical Synthesis & Biotech Co (TPE:1762) has a ROIC % of -16.11% as of Dec. 2025. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Chunghwa Chemical Synthesis & Biotech Co and its competitors.
Is Chunghwa Chemical Synthesis & Biotech Co's ROIC % too high?
Chunghwa Chemical Synthesis & Biotech Co's current ROIC % is -16.11%. Overall, Chunghwa Chemical Synthesis & Biotech Co has a GF Score™ of 58/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chunghwa Chemical Synthesis & Biotech Co's ROIC % compare to VRTX and REGN?
Chunghwa Chemical Synthesis & Biotech Co's ROIC % of -16.11% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROIC % for a Biotechnology company?
A good ROIC % depends on the Biotechnology industry context. However, ROIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROIC % mean?
A high ROIC % can signal that a stock is expensive relative to its fundamentals. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Chunghwa Chemical Synthesis & Biotech Co and its competitors. Chunghwa Chemical Synthesis & Biotech Co's current ROIC % is -16.11%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chunghwa Chemical Synthesis & Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Chunghwa Chemical Synthesis & Biotech Co (TPE:1762) is currently considered Fairly Valued. The stock's GF Value™ is NT$37.92, compared to a current price of NT$38.15 — trading 0.6% above its estimated fair value. The current ROIC % is -16.11%. Chunghwa Chemical Synthesis & Biotech Co's overall GF Score™ is 58/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROIC % calculated?
ROIC % is calculated from a company's financial statements. For Chunghwa Chemical Synthesis & Biotech Co (TPE:1762), the current ROIC % is -16.11% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chunghwa Chemical Synthesis & Biotech Co (TPE:1762) Overvalued in 2026?

Based on GuruFocus' analysis, Chunghwa Chemical Synthesis & Biotech Co stock appears to be overvalued. The current stock price of NT$38.15 is trading 0.6% above its estimated GF Value™ of NT$37.92. GuruFocus considers Chunghwa Chemical Synthesis & Biotech Co to be Fairly Valued.

Key valuation signals for TPE:1762:

  • ROIC %: -16.11%
  • GF Value™: NT$37.92 vs. price of NT$38.15 (0.6% above fair value)
  • GF Score™: 58/100 with 8 warning signs

No single metric tells the full story. See the TPE:1762 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Chunghwa Chemical Synthesis & Biotech Co Business Description

Address No. 1, Dongxing Street, Shulin District, Taipei, TWN
Chunghwa Chemical Synthesis & Biotech Co Ltd is engaged in the research, development, manufacturing, and sales of pharmaceutical products. Geographically, it derives a majority of its revenue from the United States and also has a presence in Taiwan. Its product portfolio comprises pain management, antifungal, immunosuppressant, oncology, Cardiovascular, Peptide Drugs, and Others.
58GF Score

Get the complete analysis for TPE:1762

ROIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$38.15
Price
NT$37.92
GF Value